Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.
Ahmed SawasHelen MaJohn G KuruvillaJennifer K LueChangchun DengEnrica MarchiFrancesca MontanariBin ChengKerry J SavageDiego R VillaMichael CrumpJoseph M ConnorsOwen A O'ConnorPublished in: Leukemia & lymphoma (2020)